Ziopharm Files Definitive Consent Revocation Statement and Sends Letter to Shareholders
November 02, 2020 09:00 ET
|
ZIOPHARM Oncology Inc
Urges Shareholders to Sign and Return Ziopharm’s GREEN Consent Revocation Card Emphasizes that Substantial Board Refreshment is Already in Process Reiterates Commitment to Implementing Strategy and...
Ziopharm Oncology to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020
October 29, 2020 09:00 ET
|
ZIOPHARM Oncology Inc
BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, November 5, at 4:30 pm EDT to...
Ziopharm Oncology Announces Receipt of Shareholders’ Intent to Solicit Written Consents
October 16, 2020 16:00 ET
|
ZIOPHARM Oncology Inc
BOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it has received a notice, and acknowledges the filing of, a...
Ziopharm Oncology to Participate in Jefferies Cell Therapy Virtual Summit on October 5, 2020
October 01, 2020 08:30 ET
|
ZIOPHARM Oncology Inc
BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate...
Ziopharm Oncology Appoints Kevin Buchi to its Board of Directors
September 22, 2020 08:30 ET
|
ZIOPHARM Oncology Inc
– Life Sciences industry veteran; 15-year Cephalon executive, serving progressively as CFO, COO and then CEO at time of $6.8 billion acquisition by Teva – – Doug Pagán Steps Down from Board of...
Ziopharm Oncology Appoints Four Additional Members to Scientific Advisory Board
September 15, 2020 08:30 ET
|
ZIOPHARM Oncology Inc
BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of four additional members to its Scientific Advisory...
Ziopharm Oncology Granted Rare Pediatric Disease Designation for Controlled IL-12 for the Treatment of DIPG
September 14, 2020 08:30 ET
|
ZIOPHARM Oncology Inc
BOSTON, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare...
Ziopharm Oncology to Participate in Upcoming Conferences
September 10, 2020 09:00 ET
|
ZIOPHARM Oncology Inc
BOSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate...
Ziopharm Oncology Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 06, 2020 16:04 ET
|
ZIOPHARM Oncology Inc
– Enrollment completed in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo® –– First patient with DIPG dosed in phase 1/2 pediatric brain tumor trial of Contolled IL-12 –– Work...
Ziopharm Oncology to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020
July 28, 2020 09:00 ET
|
ZIOPHARM Oncology Inc
BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, August 6, at 4:30 pm EDT to provide...